Target intelligence / Profile preview

Histone acetyltransferase 1 (HAT1)

Target
HAT1
Molecular classification
Enzyme, Histone modification enzyme, Type B histone acetyltransferase, Chromatin-modifying enzyme
01

Overview

Histone acetyltransferase 1 (HAT1) is a highly conserved enzyme responsible for the acetylation of newly synthesized histone H4 at lysine 5 and lysine 12 prior to chromatin assembly. It functions as the catalytic subunit of the type B histone acetyltransferase complex and associates with WD40 repeat-containing regulatory proteins (e.g., RbAp46/RBBP7) that enhance its activity. HAT1-mediated acetylation is crucial for chromatin replication, maturation, and is involved in transcriptional regulation by promoting nucleosome assembly and facilitating access to DNA regulatory proteins. Disruption or dysregulation of HAT1 is linked to oncogenic processes and chromatin-associated diseases, making it a relevant biological and potential therapeutic target.

Other names
HAT1KAT1histone acetyltransferase type B catalytic subunitHistone acetyltransferase 1
02

Mechanism of action

Inhibition of HAT1 would decrease histone H4 acetylation, affecting chromatin assembly and gene expression, with possible anti-cancer utility in overexpressing settings. Activation would theoretically enhance acetylation and alter chromatin accessibility and transcription.

03

Biological functions

Acetylation of newly synthesized histone H4 (at Lys5 and Lys12)Chromatin assembly and maturationRegulation of gene expressionRegulation of DNA replicationRegulation of DNA repairInteraction with histone chaperones and nuclear import of histones
04

Disease associations

Cancer (chromatin modifiers, including HAT1, can play roles in oncogenesis and tumor suppression)Other (potential links to developmental and replication disorders via chromatin regulation)
05

Safety considerations

Risks of affecting global chromatin structure, gene expression, and cell viabilityRisks of genotoxicity and impaired DNA replication when modulating HAT1
06

Interacting drugs

None are currently approved or clinical-stage drugs that selectively target HAT1 directly, based on available public domain searches
07

Biomarkers

Increased or decreased levels of HAT1 and acetylated histone H4 (Lys5/Lys12) may serve as biomarkers in cancer or chromatin dysregulation

Beyond the preview

Go deeper on Histone acetyltransferase 1 (HAT1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Histone acetyltransferase 1 (HAT1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call